Author:
Verma Nitin,Thapa Komal,Kanojia Neha,Kaur Gagandeep,Sood Parul,Dua Kamal
Publisher
Springer Nature Singapore
Reference90 articles.
1. Abushakra S, Porsteinsson A, Scheltens P et al (2017) Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer’s disease suggest disease modification potential. J Prev Alzheimers Dis 4:149–156
2. Aisen PS, Gauthier S, Ferris SH et al (2011) Tramiprosate in mild-to-moderate Alzheimer’s disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 7:102–111
3. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520
4. Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175–193
5. Carrasquillo MM, Belbin O, Zou F et al (2010) Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer’s disease. PLoS One 5:e8764